Independent Clinical Development and Life Sciences Advisory
Senior scientific and clinical-development advice for
biotech leaders, pharmaceutical executives, boards and investors.
Mathieu Ghadanfar, MD, FESC, FAHA
CARDIOLOGIST | BIOPHARMA EXECUTIVE | STRATEGIC ADVISOR
President & Founder
30+ Years Experience I Global Pharma Leadership I Clinical Development I Independent Advisory
Strategic Judgement for High Stake decisions
Independent scientific and clinical judgement on complex drug development and investment decisions combining the rigor of clinical medicine with the strategic perspective of global biopharmaceutical leadership.
Scientific Leadership
Mathieu Ghadanfar, MD, FESC, FAHA brings more than three decades of cardiovascular, clinical-development and executive experience to biotechnology, pharmaceutical and investment decisions.
Selected Advisory Experience
Independent senior-level advice for biotech leaders and pharmaceutical executives navigating complex drug-development decisions.
Biotech CEOs & Boards
Translate promising science into a credible clinical-development program, from early translation and FIH through proof-of-concept and key value inflection points.
Pharma R&D Leaders
Independent senior review of development programs, portfolios and high-impact scientific decisions.
Investors & Venture Capital
Assessment of biotechnology assets, development risk and probability of success with independent scientific and clinical input.
Senior Level
Direct, evidence-based advice for executive and board decisions.
Independent
Objective advice grounded in the science, clinical evidence and long-term development strategy.
Evidence-Driven
Rigorous assessment of clinical development assumptions, risks and evidence.
Confidential
Discreet senior advisory support for biotech leaders, boards and investors.
Services
Independent senior-level support across clinical development, Medical Affairs, portfolio decisions and scientific due diligence.
Clinical Development Strategy
Independent guidance from early clinical development and proof-of-concept through pivotal development.
Areas:
• Clinical development plan design and optimization
• Feasibility assessment and risk–benefit modeling
• Fractional or interim senior clinical-development leadership
Medical Affairs & Evidence Strategy
Senior support for evidence generation, scientific engagement and lifecycle strategy.
Areas:
• Medical Affairs team design and scale-up
• Scientific communication and KOL engagement frameworks
• Evidence generation and publication planning
• Launch readiness and post-approval support
Investment & Scientific Due Diligence
Independent scientific and clinical assessment of biotechnology assets for investors, boards and business-development teams.
Areas: :
-
Scientific and translational rationale
-
Clinical-development feasibility
-
Trial design and evidence quality
-
Competitive differentiation
-
Development risks
-
Probability of technical and clinical success
-
Key value inflection points
About Mathieu Ghadanfar, MD, FESC, FAHA
Mathieu Ghadanfar is a cardiologist and international physician-executive with more than three decades of experience across cardiovascular medicine, clinical research, global drug development and Medical Affairs.
He has held senior global leadership roles at Pfizer and Novartis and has contributed to the development and global introduction of innovative cardiovascular therapies.
Through M-Ghadanfar Consulting Life Sciences, he advises biotechnology companies, pharmaceutical leaders, boards and investors on clinical-development strategy, translational science, cardiovascular and cardiorenal innovation, Scientific Advisory Boards and investment due diligence.
His work combines clinical insight, scientific rigor and global biopharmaceutical leadership to support complex development and investment decisions.
Biopharma Executive | Former Pfizer & Novartis Leader
With a distinguished career at Pfizer and Novartis, I have led large-scale drug development programs, late-stage clinical trials, and regulatory submissions, culminating in successful product approvals and global launches. My expertise in Clinical Development and Global Medical Affairs has played a pivotal role in shaping innovative therapies and delivering transformative healthcare solutions.
Clinical and scientific background
Holding an MD and a Board certificate in Cardiology and Vascular Medicine from Paris, complemented by diplomas in Echocardiography, Pharmacology, and Clinical Trials Methodology, I bring a strong scientific and clinical foundation to my work. As a French citizen based in Switzerland, I have led multicultural teams across Europe and the US, fostering global collaborations and advancing medical innovation in diverse regulatory environments.
Affiliations, Recognitions
-
Global Fellow in Medicines Development (GFMD) – IFAPP
-
Fellow of the European Society of Cardiology (FESC)
-
Fellow of the American Heart Association (FAHA)
-
Gold Member, Heart Failure Association of the European Society of Cardiology
-
Member of the French Society of Cardiology
-
Member of the Hypertension and Stroke Councils of ESC
Publication
Author and co-author of peer-reviewed publications in cardiovascular medicine, clinical research and drug development. PubMed →https://pubmed.ncbi.nlm.nih.gov/?term=ghadanfar+m
Facing a critical development or investment decision?
M-Ghadanfar Consulting works selectively with biotech companies,
pharmaceutical organizations, boards and investors.
Discuss Your Project
All enquiries are treated confidentially.
